Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 3,341 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares in the company, valued at approximately $2,788,059.18. This trade represents a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Cytokinetics Stock Up 2.5 %
CYTK traded up $1.09 during trading on Tuesday, reaching $44.40. The company had a trading volume of 1,967,343 shares, compared to its average volume of 1,575,645. The company has a market cap of $5.26 billion, a P/E ratio of -8.25 and a beta of 0.95. The business's fifty day moving average price is $46.59 and its 200 day moving average price is $50.57. Cytokinetics, Incorporated has a 12 month low of $40.53 and a 12 month high of $75.71. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million. Equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.
Institutional Trading of Cytokinetics
Institutional investors and hedge funds have recently made changes to their positions in the company. Jones Financial Companies Lllp raised its position in Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Cytokinetics during the fourth quarter valued at approximately $29,000. AlphaQuest LLC grew its position in Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp increased its position in shares of Cytokinetics by 62.1% during the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 671 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 842 shares during the period.
Analyst Ratings Changes
CYTK has been the topic of several analyst reports. Mizuho raised their price objective on Cytokinetics from $99.00 to $103.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Evercore ISI upgraded Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Citigroup started coverage on shares of Cytokinetics in a research note on Friday, February 7th. They set a "buy" rating and a $86.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research note on Friday, February 28th. Finally, Stifel Nicolaus started coverage on Cytokinetics in a research report on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $82.00.
Get Our Latest Stock Report on Cytokinetics
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Recommended Stories
Before you consider Cytokinetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.
While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
